在癌中SLC1A1/EAAT3-选择性抑制剂的机制和结构引导优化
Pooneh Koochaki1, Biao Qiu2,3, Jesse A Coker4
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195.
研究人员发现了一种针对SLC1A1/EAAT3的新方法,SLC1A1/EAAT3是细胞癌 (RCC) 中的关键载体. 一种新型的抑制剂与独特的口袋结合,阻断传送器功能,并显示出对RCC治疗的希望.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 在瘤学瘤学.
背景情况:
- 细胞癌 (RCCs) 呈现出对SLC1A1/EAAT3载体的代谢依赖.
- 对SLC1A1/EAAT3的药理向具有重大挑战.
- 了解SLC1A1/EAAT3抑制的结构基础对于治疗开发至关重要.
研究的目的:
- 为了确定人体SLC1A1/EAAT3与抑制剂3e结合的冷-EM结构.
- 为了阐明双循环的伊米达佐[1,2-α]皮里丁-3-胺 (BIA) 衍生物对SLC1A1/EAAT3的结合机制和性抑制.
- 引导开发用于RCC治疗的新型,更强大的SLC1A1/EAAT3抑制剂.
主要方法:
- 低温电子显微镜 (cryo-EM) 用于确定人类SLC1A1/EAAT3.3的结构.
- 生物化学测定以评估抑制剂结合和运输活性.
- 位点导向的突变发生,以调查全结合口袋的作用.
- 药用化学合成新型BIA衍生物.
主要成果:
- 冷-EM结构显示,化合物3e与SLC1A1/EAAT3.3的apo状态中的嵌入膜的全囊结合.
- 抑制包括阻断基质和结合,并防止必要的运输运动.
- 在全囊中的突变取消了RCC细胞中的3e结合及其细胞毒性.
- 新开发的BIA衍生物PBJ1和PBJ2通过SLC1A1/EAAT3抑制显示出增强的细胞毒性.
结论:
- 化合物3e通过结合到一个独特的全位,有效地抑制SLC1A1/EAAT3.
- 鉴定的结合部位和机制为设计选择性SLC1A1/EAAT3抑制剂提供了基础.
- 以结构为导向的BIA衍生品开发提供了一个有前途的治疗策略,通过准代谢脆弱性来对抗RCC.
更多相关视频
10:58Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Elimination by Renal Route: Tubular Secretion
ABC Transporters: Exporter
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies
There are several types of targeted therapies against...
